[Clinical results obtained with a new anti-inflammatory preparation, PIR-353 and indoarginine combination].
D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001120:Arginine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007659:Ketones / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000081:Acetamides; D000893:Anti-Inflammatory Agents; D007211:Indoles; D007659:Ketones; D011724:Pyridazines; D001120:Arginine; C003485:isamfazone
Resultados clínicos obtenidos con un nuevo preparado antinflamatorio. Asociación de PIR-353 e indoarginina.